Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

Natera's earnings call highlights strong financial performance, with a 37% YoY revenue increase and a 63% gross margin. The company is cash flow positive with nearly $1 billion in cash and no debt. Despite competitive pressures and supply chain challenges, Natera's innovation roadmap, clinical trials, and AI tools deployment are promising. The Q&A session reveals strong market interest and potential growth in oncology volumes. While management was unclear on some specifics, the overall sentiment is positive, supported by optimistic guidance and shareholder returns. These factors suggest a positive stock price movement.

Key Financial Performance

Revenue $502 million (up 37% year-on-year from $368 million in Q1 2024) due to outstanding volume growth and increased average selling prices (ASPs).

Gross Margin 63% (up from 52% year-on-year) with an underlying gross margin improvement to 60.4% in Q1 2025, driven by ASP growth and scale efficiencies.

Cash Generated $23 million in cash generated during the quarter, reflecting strong operational performance despite increased investments in growth.

Units Processed 855,000 units processed (up 8% sequentially from Q4 2024), with significant growth in women's health and oncology volumes.

Average Selling Price (ASP) for Signatera Above $1,100, driven by improved Medicare Advantage reimbursement.

Loss per Share Reduced loss per share compared to the previous year, despite increased R&D and SG&A expenses.

Cash Position Nearly $1 billion in cash with no debt outside of a line of credit.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

Signatera: Signatera clinical volumes grew 52% year-on-year and increased by roughly 16,500 units compared to Q4, marking the best sequential unit quarter.

Prospera: Prospera demonstrated the ability to predict clinical outcomes in heart transplantation, outperforming biopsy in predicting graft dysfunction.

Signatera Genome: The Genome version of Signatera is now broadly available, detecting ctDNA at frequencies as low as a single tumor copy per million.

Revenue Growth: Generated $502 million in revenue this quarter, a 37% increase compared to $368 million in Q1 of last year.

Market Guidance: Raised revenue guidance for the year to $1.94 billion to $2.02 billion, an increase of $70 million from prior guidance.

ASP Growth: Signatera ASPs moved above $1,100, driven by securing Medicare Advantage reimbursement.

Gross Margin: Gross margins were 63% in the quarter, with an underlying improvement of about 110 basis points from Q4.

Cash Generation: Generated $23 million in cash while investing in growth.

Volume Processed: Processed 855,000 units in the quarter, with significant growth in Women's Health and Organ Health.

Clinical Trials: Presented data at ISHLT and upcoming ESMO Breast Annual Meeting, focusing on Signatera's predictive capabilities.

Expansion into New Histologies: Pursuing rapid expansion into new cancer types, including sarcoma, with significant clinical data supporting Signatera's utility.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Regulatory Issues: The company acknowledges potential risks related to regulatory changes that could impact their operations and product approvals.

Competitive Pressures: Natera faces significant competition in the oncology and diagnostics market, which could affect their market share and pricing strategies.

Supply Chain Challenges: There are concerns regarding supply chain disruptions that could impact the availability of materials needed for testing and product development.

Economic Factors: Economic downturns or changes in healthcare funding could affect patient access to testing and overall demand for Natera's products.

Investment Risks: The company is heavily investing in growth initiatives, which carries the risk of not achieving expected returns or market acceptance.

Market Adoption: There is uncertainty regarding the adoption of new products and technologies, particularly in the oncology space, which could impact revenue projections.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

Revenue Growth: Natera generated $502 million in revenue for Q1 2025, representing a 37% year-on-year growth.

Volume Growth: 855,000 units processed in Q1 2025, with significant growth in women's health and oncology.

Prospera Study: Positive results from the DEFINE study in heart transplantation, showing Prospera's ability to predict clinical outcomes.

Signatera Expansion: Signatera clinical volumes grew 52% year-on-year, with a focus on expanding clinical utility and innovation.

New Indications: Natera is pursuing expansion into new histologies, including sarcoma, with promising data from recent studies.

Revenue Guidance: Raised revenue guidance for 2025 to a range of $1.94 billion to $2.02 billion, an increase of $70 million from prior guidance.

Gross Margin Guidance: Maintained gross margin guidance at 60% to 64% for the full year.

Cash Flow: Generated $23 million in cash flow in Q1 2025, with plans to remain cash flow breakeven for the year.

Investment Strategy: Continued investment in growth opportunities, particularly in Signatera, with a long-term revenue potential exceeding $5 billion.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

Shareholder Return Plan: Natera generated $23 million in cash during Q1 2025, indicating a positive cash flow position. The company is focused on maintaining a cash flow breakeven status while investing in growth opportunities, particularly in Signatera, which is expected to drive significant revenue growth in the future.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:Can you give a little flavor what's going on in the market, kind of what drove it, just kind of volume was sustainable as we go through the year?

A:We're really pleased, record sequential quarter in growth. The data generated, performance of the test, and strong clinical utility is resonating with physicians. We're not changing the previous quarter-over-quarter sequential growth, which we said was around like 10,000 to 12,000 units roughly.

Q:Which of these studies do you think we should focus on over the next year that can really begin to move the needle on actual volumes in the marketplace?

A:We're excited to have more than 25 presentations at ASCO, including six oral presentations. Strong presence in breast cancer and gastrointestinal cancers. The DARE study is generating a lot of excitement.

Q:Is there a delta in terms of the number of tests reimbursed for breast versus CRC in the recurrent setting?

A:There are differences in reimbursement cadences for different tumor sites, but I can't get into the details on each particular tumor site.

Q:Did you see any disruption from either like weather or calendar day dynamics in the first quarter?

A:Weather was a huge challenge, particularly with the wildfires in Southern California, but we were able to power through it.

Q:Can you walk us through which indication did you see the greatest sequential growth for Signatera volumes?

A:We're seeing a lot of interest across the board, including colorectal, breast, lung, muscle invasive bladder, and ovarian cancers.

Q:What are you assuming on the screening front?

A:We have the PROCEED study that has met the goal of enrolling more than 3,000 patients and will read out toward the end of the year.

Q:Can you talk a little bit more about the COGS improvement initiatives?

A:There's certainly room for COGS improvements, and we have larger scale projects underway. There's also COGS reductions that come with scale.

Q:Can you just remind us the timeline and path forward for Japan?

A:We're on track with our submission to the PMDA in Japan, expecting approval towards the end of the year or early next year.

Q:How do you see the whole genome fitting into your portfolio?

A:We're seeing some interest in the whole genome test, but physicians are largely supportive of the peer review data from the exome-based test.

Q:Review of Unclear Management Responses

A:Management avoided giving a direct answer regarding the specific reimbursement differences for breast versus CRC tests, stating that there are differences but not providing details. Additionally, there was a lack of clarity on the exact impact of weather disruptions on volumes, as management indicated it was hard to see in the volumes despite acknowledging the challenges.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

NTRA Transcript

Natera, Inc. (NTRA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Neutral11-20

Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-19

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

Positive11-6

The earnings call highlights several positive factors: raised revenue and gross margin guidance, strong cash flow expectations, and strategic investments in new product launches and clinical trials. Despite some vague responses in the Q&A, the overall sentiment is positive due to optimistic guidance, Medicare reimbursement expansion, and AI-driven efficiencies. The raised guidance and strong financial metrics, coupled with the positive outlook for future growth, suggest a likely positive stock price movement over the next two weeks.

Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Neutral9-24

NTRA Slides

Natera Q1 2025 slides: 37% revenue growth drives raised guidance

2025-05-08

Natera Q2 2025 slides: 32% revenue growth drives raised guidance, stock surges

2025-08-07

Natera Q3 2025 slides: Revenue soars 35%, guidance raised despite EPS miss

2025-11-06

NTRA Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.